



Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support

Fabian Falkenbach¹ · Sophie Knipper¹ · Daniel Koehler² · Francesca Ambrosini^{1,3} · Thomas Steuber^{1,4} · Markus Graefen¹ · Lars Budäus¹ · Matthias Eiber⁵ · Lukas Lunger⁶ · Flemming Lischewski⁶ · Matthias M. Heck⁶ · Tobias Maurer^{1,4}

Received: 11 April 2023 / Accepted: 6 July 2023 / Published online: 29 July 2023
© The Author(s) 2023

Abstract

Background and objective Metastasis-directed therapy is a feasible option for low PSA, recurrent locoregional metastatic prostate cancer. After initial salvage surgery, patients with good response might consider a repeat salvage surgery in case of recurrent, isolated, and PSMA-positive metastases. This analysis aimed to evaluate the oncological outcome and safety of repeat PSMA-targeted radioguided surgery (RGS) after either prior RGS or “standard” salvage lymph node dissection (SLND).

Materials and methods We identified 37 patients undergoing repeat RGS after prior SLND ($n = 21$) (SLND-RGS) or prior RGS ($n = 16$) (RGS-RGS) between 2014 and 2021 after initial radical prostatectomy with or without pelvic radiation therapy at two German tertiary referral centers. Kaplan–Meier analyses and uni-/multivariable Cox regression models were used to investigate factors associated with biochemical recurrence-free survival (BRFS) and treatment-free survival (TFS) after repeat salvage surgery.

Results and limitations Complete Biochemical Response (cBR, PSA < 0.2 ng/ml) was observed in 20/32 patients (5 NA). Median overall BRFS [95% confidence interval (CI)] after repeat salvage surgery was 10.8 months (mo) (5.3–22). On multivariable regression, only age (HR 1.09, 95% CI 1.01–1.17) and preoperative PSA (HR 1.23, 95% CI 1.01–1.50) were associated with shorter BRFS, although PSA (HR 1.16, 95% CI 0.99–1.36) did not achieve significant predictor status in univariable analysis before (p value = 0.07). Overall, one year after second salvage surgery, 89% of the patients (number at risk: 19) did not receive additional treatment and median TFS was not reached. Clavien–Dindo grade > 3a complications were observed in 8% (3/37 patients). Limitations are the retrospective evaluation, heterogeneous SLND procedures, lack of long-term follow-up data, and small cohort size.

Conclusion In this study, repeat RGS was safe and provided clinically meaningful biochemical recurrence- and treatment-free intervals for selected cases. Patients having low preoperative PSA seemed to benefit most of repeat RGS, irrespective of prior SLND or RGS or the time from initial RP/first salvage surgery.

Keywords Hormone-sensitive · PET · Positron emission tomography · Metastasis directed therapy · Pelvic recurrence

Introduction

The management of biochemical failure after curative intent primary treatment with the detection of oligo-metastatic recurrence of prostate cancer (PCa) remains challenging. Despite a shortage of prospective studies, emerging data support the role of metastasis-targeted therapies (MDT). By this, initiation of systemic treatment may be postponed in

Fabian Falkenbach, Sophie Knipper, Matthias M. Heck and Tobias Maurer have contributed equally.

Extended author information available on the last page of the article

selected cases, either by surgery or radiation [1–3]. However, delayed or immediate androgen deprivation therapy (ADT) often constitutes the standard of care for these patients [4]. Salvage lymph node dissection (SLND) for nodal recurrence can achieve a complete biochemical response (cBR, defined as postoperative PSA of 0.2 ng/ml or below) in 28% [5] up to 46% [6] and prolong ADT-free survival compared to expectant management alone [2, 7].

In a small case series, repeat SLND achieved cBR in 4 out of 10 patients, and the median time to PSA relapse to the preoperative value was 23 months for repeat SLND [8]. Accordingly, MDT, even in a repeat setting, might improve cancer-specific survival compared with the standard of care for nodal, oligo-recurrent prostate cancer [9]. In a long-term follow-up, MDT might even be curative in a very small proportion of patients, while most patients are likely to require a multimodal approach [10, 11].

Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has led to the detection of small, localized recurrence of prostate cancer at low PSA values [12, 13]. Especially, these patients seem to benefit most from MDT. In a systematic review from 2019, the 2 and 5 years biochemical progression-free survival rates after SLND with prior PSMA PET imaging ranged from 23 to 64% and from 6 to 31%, respectively [14]. Salvage Surgery using RGS increases cancer extraction yield by extensive in vivo and ex vivo measurements and immediate feedback for the surgeon [15–17], while providing a reasonable safety profile [18]. The RGS approach offers hereby the precision needed for the definitive treatment of small nodal recurrence [17] and therefore became a routine procedure in open and even robotic surgery [19] at our institutions. In selected cases with a low preoperative PSA value and a single lesion, RGS can achieve cBR in up to 84% [20].

However, the question remains if it is reasonable to offer selected patients a repeat salvage RGS after failure of initial SLND or RGS. We therefore aimed to evaluate the oncological outcome and safety of repeat PSMA-RGS after either prior RGS or “standard” SLND.

Patients and methods

Patients

Within the prospectively collected clinical database of two tertiary care centers with 524 RGS procedures, we identified 37 patients, who received a repeat RGS for oligo-metastatic recurrence of hormone sensitive prostate cancer between 2014 and 2021 after prior SLND or RGS after initial radical prostatectomy with or without pelvic radiation therapy. All patients received PSMA PET imaging prior referral for surgery. We excluded two patients with repeat RGS performed

elsewhere (without documentation) and two patients with atypical metastasectomy (cervical, visceral). All patients were informed about the experimental nature of PSMA-radioguided SLND and provided informed consent for the procedure and data analysis. This retrospective analysis was approved by the institutional review boards of Hamburg (2019-PS-09; PV7316) and Munich (number 336/18 S), Germany. Questionnaires were used for the follow-up. All data were prospectively stored in an institutional database (FileMaker Pro 10; FileMaker Inc., Santa Clara, CA, USA).

Procedure of (repeat) salvage surgery using RGS

Repeat RGS procedures were performed as reported for initial RGS procedures [16, 19, 21, 22]. Radioguidance was achieved through extensive in vivo and ex vivo measurements using a gamma probe (Crystal Probe CXS-SG603 or DROP-IN gamma probe; Crystal Photonics, Berlin, Germany) with acoustic and numerical feedback as a response to ^{99m}Tc radioactivity. Further excision/search is prompted in cases of insufficient ex vivo signals [16]. All RGS procedures were performed by experienced, high-volume surgeons.

Outcomes of interest

Biochemical recurrence-free survival (BRFS, defined as postoperative PSA < 0.2 ng/ml without further treatment) and treatment-free survival (TFS, defined as survival without further therapy) as well as in comparison to the BRFS after initial SLND / RGS and after RP were evaluated. Furthermore, the rate of cBR (defined as PSA < 0.2 ng/ml) without additional treatment was determined 2–16 weeks following repeat salvage surgery. The time between the first and second salvage surgeries and the time between RP and first salvage surgery were measured. Postoperative complications were classified according to Clavien–Dindo [23].

Statistical analyses

Descriptive statistics included frequencies and proportions for categorical variables. The medians and interquartile ranges (IQR) were reported for continuously coded variables. The statistical significance of differences in medians and proportions was evaluated using the Kruskal–Wallis and Chi-square tests, respectively. For comparison of contingency tables, the Fisher’s exact test was applied. Kaplan–Meier plots graphically depict the BRFS and cBR after repeat salvage surgery. Univariable and multivariable Cox regression models were used to investigate the association between oncological outcomes (BRFS, cBR, TFS) and selected variables [age at repeat surgery (continuously coded), Gleason Grade Group at RP (I–II vs. III–V),

radiation therapy post RP (yes vs. no), time between initial SLND/RGS and repeat RGS (continuously coded), PSA at repeat RGS (continuously coded), number of PSMA PET-positive lesions prior to repeat RGS (continuously coded), and localization of PSMA PET-positive lesions (pelvic vs. retroperitoneal and pelvic vs. retroperitoneal only)]. All tests were two sided, with the significance level set at $p < 0.05$. The R software environment for statistical computing and graphics (version 3.4.3, R Foundation for Statistical Computing) was used for all statistical analyses.

Results

Patients' characteristics and comparison of groups

Of the 37 patients who underwent repeat salvage surgery using RGS after prior SLND ($n = 21$) or RGS ($n = 16$), all received RP as primary treatment. Baseline characteristics at RP were similar among both groups with a tendency for more severe disease in the RGS-RGS cohort (supplementary Table 2). Of note, only 3/16 (RGS-RGS) and 4/21 (SLND-RGS) of patients (equals 19% in both groups) were initially

lymph node positive at RP. Initial lymph node dissection at RP was performed in 33 of 37 patients (89%).

At initial salvage surgery, specimens removed were without histological proof of cancerous tissue in 1 of 16 patients (6%) undergoing RGS and 6 of 21 patients (29%) undergoing SLND. The median age at repeat salvage surgery was 70 years (IQR: 62–74 years, RGS–RGS) or 69 years (IQR: 65–70 years, SLND–RGS). Patients after SLND had a higher median PSA before repeat salvage surgery (RGS–RGS: 0.66 ng/ml vs. SLND–RGS: 1.16 ng/ml), while the number of pathologically positive lesions was comparable ($p = 0.37$). All patients showed 1–3 metastatic soft tissue lesions, as determined by PSMA PET imaging (Table 1).

Oncological outcomes

At 2–16 weeks after repeat salvage surgery, 20/32 patients (63%, 5 NA) achieved cBR. The median (IQR) follow-up for patients who did not experience biochemical recurrence was 9.0 (3.9–12.3) months. The median (IQR) follow-up for patients who did not receive further therapy was 10.8 (5.7–25.0) months. One year after repeat salvage surgery, 43% of the patients (number at risk: 10) did not experience

Table 1 Baseline characteristics at initial and repeat salvage surgery of the 37 patients included in this study

	RGS-RGS, ($n = 16$)		SLND-RGS ($n = 21$)	
	1. RGS	2. RGS	1. SLND	2. RGS
Time between RP and salvage surgery, months, medians (IQR)	58 (44, 111)	90 (70, 126)	63 (24, 96)	88 (50, 141)
Time between first and repeat salvage surgery, months, medians (IQR)	28 (18, 36)		25 (10, 41)	
Age at salvage surgery, median (IQR)	68 (60, 72)	70 (62, 74)	65 (63, 68)	69 (65, 70)
PSA prior to salvage surgery, ng/ml, median (IQR)	0.84 (0.35, 2.03)	0.66 (0.42, 1.31)	0.50 (0.28, 2.09)	1.16 (0.89, 2.25)
PSMA PET avid lesions prior salvage, n (%)				
1	12 (75%)	9 (56%)	3 (14%)	13 (62%)
2	2 (13%)	6 (38%)	0	7 (33%)
3	2 (13%)	1 (6%)	0	1 (5%)
NA	0	0	18 (86%)	0
Total number of avid lesions treated per cohort	22	22		21
PSMA PET localization, n (%) ^a				
Pelvic	14 (88%)	11 (69%)	3 (14%)	19 (91%)
Retroperitoneal	2 (6%)	5 (31%)	0	2 (10%)
NA	0	0	18 (86%)	0
Removed metastasis, n (%)				
No cancer removed	1 (6%)	2 (13%)	6 (29%)	0
1	8 (50%)	6 (38%)	3 (14%)	11 (52%)
2	3 (19%)	5 (31%)	3 (14%)	5 (24%)
3	2 (13%)	3 (19%)	0	1 (5%)
≥ 4	2 (13%)	0	0	4 (19%)
			NA: 9 (43%)	

RGS PSMA-targeted radioguided surgery, SLND salvage lymph node dissection, RP radical prostatectomy, PSA prostate-specific antigen, NA not assigned, RT radiotherapy, IQR interquartile range

^aThe sums of pelvic and retroperitoneal PET location may exceed the number of patients due to metastasis on both locations

biochemical recurrence. One year after repeat salvage surgery, 89% of the patients (number at risk: 19, supplementary Fig. 3) did not receive additional treatment. The median overall BRFS (95%-CI) after repeat salvage surgery was 10.8 months (5.3–22.3, Fig. 1) and the median TFS was not reached (supplementary Figs. 3 and 4). None of the patients died during follow-up.

In univariable Cox regression analyses, age (HR 1.06, 95% CI 1.00–1.12), pN1 at RP (HR 2.72, 95% CI 1.03–7.18), number of lesions on PSMA PET (HR 2.14, 95% CI 1.1–4.17), and combined pelvic/retroperitoneal localization (HR 3.93, 95% CI 1.05–14.71) were significantly associated with shorter BRFS in the overall population ($p < 0.05$, supplementary Table 3). Although preoperative PSA (HR 1.16, 95% CI 0.99–1.36) did not achieve significant predictor status in univariable analysis ($p = 0.07$), it was included in multivariable analysis because of small sample size and our experiences in earlier studies [24].

In multivariable Cox regression analyses, only age (HR 1.09, 95% CI 1.01–1.17) and preoperative PSA (HR 1.23, 95% CI 1.01–1.50) were independently associated with shorter BRFS ($p < 0.05$).


Patient safety

The rate of major complications (Clavien–Dindo grade ≥ 3) within the entire cohort was 3/37 patients (8%). Of those, 2/3 cases were in patients who had previous radiation therapy. All major complications were due to bowel injury (Supplementary Table 4). These were treated in one case by simple suture (for minor rectal injury) and in two cases by the creation of an enterostomy (for sigma perforation). Interestingly, these complications were all reported in the SLND-RGS group. There were no major complications at RGS after prior RGS. Given the small sample size these differences are not statistically significant ($p = 0.09$).

Discussion

To our knowledge, this is the first study on repeat salvage surgery for oligo-recurrent metastatic prostate cancer using the enhanced capabilities of RGS. Here, patients can be generally classified into two subgroups: those with insufficient initial salvage surgery and those with repeated recurrence

Fig. 1 Kaplan–Meier analyses depicting biochemical recurrence-free survival rates in 37 patients treated with repeat PSMA-RGS after initial SLND or prior PSMA-RGS



after successful initial salvage surgery. In the first subgroup, RGS confirmed its higher tumor removal rate, especially after prior template dissection (in all patients in this group cancerous tissue was removed). As stated before, data on repeat salvage surgery are limited; therefore, oncological comparison of the RGS vs. SLND for repeat salvage surgery is not possible. In a case series of ten patients, positive lymph nodes were removed in 90% and a cBR was observed in 40% at repeat SLND [8]. Within our cohort using RGS, we achieved a positive retrieval rate of 95% and cBR of 63%. The retrieval rate of repeat RGS was also consistent with the initial RGS in this study (94%). Interestingly, the only two cases of repeat RGS without cancer removal were observed in patient with prior RGS. In conclusion, the advantages of RGS in the repeat setting are similar to the initial salvage surgery situation [15].

Concerning the proposed subgroup of patients with sufficient initial salvage surgery and true second oligo-recurrence, it is worth comparing repeat with initial salvage surgery. Still, even initial SLND itself is considered an experimental therapy. In our own cohort, as previously reported [22], cBR was observed in 78% of all patients receiving initial RGS, compared to 63% in repeat RGS. Although this difference can partly be explained by the worse baseline characteristics and potential negative selection bias of our repeat salvage surgery group, the TFS at 1 year of follow-up was similar (88% for initial vs. 89% for repeat RGS). The efficiency of RGS in the repeat setting was further confirmed by our cBR rates in the repeat setting as compared with those of (initial) SLND. In a systematic review, cBR rates ranged from 13 to 80% (mean 44%) in comparison to our 63% for the repeat setting, while TFS at 1 year was not reported [14]. Furthermore, the influence of treatment timing within metastasis-directed therapy has not been sufficiently analyzed. Slow PSA kinetics at BCR, which may be found as a surrogate parameter for slow development of new lesions, has a preferable risk profile [25]. The shorter median time between RP and first salvage (61 months, IQR: 32–102 months) vs. first salvage and second salvage surgery (28 months, IQR: 14–41 months) may indicate increasing aggressivity within this pre-selected cohort ($p = 0.26$), although validity of this statement may be limited due to adjuvant radiation therapy after RP in half of the patients. Consequently, the shorter time for BRFS for repeat RGS is plausible. To summarize, while it remains partly controversial, if MDT prolongs time to initiation of systemic treatment or castration-resistance or might even cure oligo-recurrent PCa [2], repeat salvage SLND using RGS shows similar efficacy as in the initial salvage situation and thus may potentially be offered patients with the same limitations as in the initial setting.

In view of the unproven oncological benefit of repeat RGS, patient safety is, however, of utmost importance. The

rate of major complications (Clavien–Dindo score ≥ 3) was 8%. Given our small sample size, this rate is similar to our previously reported major complication rate of 7% following RGS [24]. In comparison, in a systematic review by Plousard et al., the rate of major complications for (initial) SLND varied among all studies between 0 and 20% (grade IIIa) and 16% (grade IIIb) [14]. In a pooled analysis, major complications occurred in 9% of SLND [26]. Although data for repeat salvage surgery remain limited, Grabbert et al. reported an overall major complication rate of at least 22% in a small case series [8]. Nevertheless, the high rate of bowel injury is disturbing and may be caused by two prior surgeries in the region.

However, the main key for initial as well as repeat RGS remains patient selection, as this is not a “one-size-fits-all” approach. On multivariable analysis, only age and PSA prior repeat RGS were significantly associated with shorter BRFS. A higher preoperative PSA value (often with a proposed cut-off of 4 ng/ml) has been correlated with worse outcomes after SLND [7, 11, 27, 28]. In accordance therewith, PSA at therapy has been reported as predictive factor for salvage treatment in general [29]. Also, localization and number of PET-positive lesions have been described predictive factors for salvage treatment [3, 24, 29] and were confirmed as such here. In contrast, Gleason grade group at RP and adjuvant radiotherapy did not reach statistical significance as also previously described by Suardi et al. [27]. Interestingly enough and contrary to our initial belief, the time between initial and repeat salvage surgeries did not translate in different outcomes. Although patients with RGS after SLND had a higher PSA at second RGS and the time between first and second salvage surgeries was shorter, patients in both groups had similar rates of PSMA PET-positive lesions and pathologically proven metastasis resected at the second RGS. This is also remarkable as the RGS-RGS group had more adverse pathology at initial RP.

Nevertheless, the results of our analysis must be interpreted with caution. First, a control group is lacking. Such a group might consist of patients undergoing watchful waiting/active surveillance, radiotherapy, and/or systematic treatment regimens. Randomized prospective studies in this field of targeted surgical treatment are highly desired. Most of our patients presented asymptomatic with a low PSA in an oligo-recurrent setting. Thus, those patients do not face imminent life-threatening risks, but the side effects of continuous systemic therapy once initiated upon further progression. Recently, long-term outcomes of SLND were reported to be somewhat disappointing [10]. High-level evidence for SLND and even more so for repeat SLND is missing [14], while phase II trials like ORIOLE demonstrated less progression under MDT vs. expectant management for radiation therapy [2, 30]. However, follow-up was too short and the cohort size

too small to evaluate clinically significant endpoints. Also in our study, cBR and TFS without standardized trigger for next treatment are weak surrogate endpoints. Furthermore, the effect of selection bias on many different layers should not be underestimated. Finally, the small sample size limits the statistical validity and especially the multivariable analysis with six variables is prone to overfitting, which may introduce bias. However, the applied statistical tests and modeling were primarily calculated for exploratory purposes to compare both groups. Furthermore, a larger sample size is difficult to obtain in this setting of repeat SLND as it represents a procedure for highly selected patients treated only at expert centers. Therefore, this sample is still extremely valuable.

Conclusion

In selected cases, repeat RGS might delay the need for systemic treatment, while offering a reasonable safety profile. The effectiveness is independent of time from initial RP or first salvage surgery, adjuvant radiotherapy after RP, or the kind of initial salvage surgery (RGS/ SLND). Limitations are a missing control group, the retrospective evaluation, the small cohort, and lack of long follow-up data.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00345-023-04534-5>.

Acknowledgements This research received no specific grants from any funding agency in the public, commercial, or not-for-profit sectors.

Author contributions FF: data collection and analysis, manuscript writing/drafting. SK: project conception and development, data analysis, editing. DK: critical revision of the manuscript/editing. FA: critical revision of the manuscript/editing. TS: critical revision of the manuscript/editing. MG: critical revision of the manuscript/editing. LB: critical revision of the manuscript/editing. ME: critical revision of the manuscript/editing. LL: data analysis. FL: data collection. MMH: general oversight, supervision, critical revision. TM: project conception and development, general oversight.

Funding Open Access funding enabled and organized by Projekt DEAL. None.

Declarations

Conflict of interest The authors declare that they have no actual or potential conflicts of interest.

Informed consent Written informed consent was obtained from all patients. The authors declare that they have no conflict of interest according to the current manuscript. All authors of this research paper directly participated in the planning, execution, or analysis of the study. All the authors of this paper have read and approved the final submitted version. The contents of this manuscript have not been copyrighted or previously published. The content of this manuscript is not under consideration for publication elsewhere.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Battaglia A, De Meerleer G, Tosco L et al (2019) Novel Insights into the management of oligometastatic prostate cancer: a comprehensive review. *Eur Urol Oncol* 2(2):174–188. <https://doi.org/10.1016/j.euo.2018.09.005>
2. Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. *J Clin Oncol* 36(5):446–453. <https://doi.org/10.1200/JCO.2017.75.4853>
3. Ost P, Bossi A, Decaestecker K et al (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. *Eur Urol* 67(5):852–863. <https://doi.org/10.1016/j.eururo.2014.09.004>
4. Cornford P, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. *Eur Urol* 79(2):263–282. <https://doi.org/10.1016/j.eururo.2020.09.046>
5. Porres D, Pfister D, Thissen A et al (2017) The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. *Prostate Cancer Prostatic Dis* 20(1):85–92. <https://doi.org/10.1038/pcan.2016.54>
6. Jilg CA, Rischke HC, Reske SN et al (2012) Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. *J Urol* 188(6):2190–2197. <https://doi.org/10.1016/j.juro.2012.08.041>
7. Tilki D, Mandel P, Seeliger F et al (2015) Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. *J Urol* 193(2):484–490. <https://doi.org/10.1016/j.juro.2014.08.096>
8. Grabbert M, Sigle A, Lang L et al (2022) Long-term clinical outcomes of repeat salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: a case series. *Eur Urol Focus* 8(2):425–430. <https://doi.org/10.1016/j.euf.2021.03.025>
9. Steuber T, Jilg C, Tennstedt P et al (2019) Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. *Eur Urol Focus* 5(6):1007–1013. <https://doi.org/10.1016/j.euf.2018.02.015>
10. Bravi CA, Fossati N, Gandaglia G et al (2020) Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought. *Eur Urol* 78(5):661–669. <https://doi.org/10.1016/j.eururo.2020.06.043>
11. Rigatti P, Suardi N, Briganti A et al (2011) Pelvic/Retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal

- recurrence detected by [11C]choline positron emission tomography/computed tomography. *Eur Urol* 60(5):935–943. <https://doi.org/10.1016/j.eururo.2011.07.060>
12. Rauscher I, Maurer T, Beer AJ et al (2016) Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. *J Nucl Med* 57(11):1713–1719. <https://doi.org/10.2967/jnumed.116.173492>
 13. Afshar-Oromieh A, da Cunha ML, Wagner J et al (2021) Performance of [(68)Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients. *Eur J Nucl Med Mol Imaging* 48(9):2925–2934. <https://doi.org/10.1007/s00259-021-05189-3>
 14. Ploussard G, Gandaglia G, Borgmann H et al (2019) Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review. *Eur Urol* 76(4):493–504. <https://doi.org/10.1016/j.eururo.2018.10.041>
 15. Knipper S, Tilki D, Mansholt J et al (2019) Metastases-yield and prostate-specific antigen kinetics following salvage lymph node dissection for prostate cancer: a comparison between conventional surgical approach and prostate-specific membrane antigen-radioguided surgery. *Eur Urol Focus* 5(1):50–53. <https://doi.org/10.1016/j.euf.2018.09.014>
 16. Maurer T, Robu S, Schottelius M et al (2019) (99m)technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. *Eur Urol* 75(4):659–666. <https://doi.org/10.1016/j.eururo.2018.03.013>
 17. Koehler D, Sauer M, Klutmann S et al (2022) Feasibility of (99m) Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients. *J Nucl Med*. <https://doi.org/10.2967/jnumed.122.263892>
 18. Siriwardana A, Thompson J, van Leeuwen PJ et al (2017) Initial multicentre experience of (68) gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. *BJU Int* 120(5):673–681. <https://doi.org/10.1111/bju.13919>
 19. de Barros HA, van Oosterom MN, Donswijk ML et al (2022) Robot-assisted prostate-specific membrane antigen–radioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe: the first prospective feasibility study. *Eur Urol* 82(1):97–105. <https://doi.org/10.1016/j.eururo.2022.03.002>
 20. Horn T, Krönke M, Rauscher I et al (2019) Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigen-targeted radioguided surgery in recurrent prostate cancer. *Eur Urol* 76(4):517–523. <https://doi.org/10.1016/j.eururo.2019.03.045>
 21. Rauscher I, Duwel C, Wirtz M et al (2017) Value of (111) In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. *BJU Int* 120(1):40–47. <https://doi.org/10.1111/bju.13713>
 22. Knipper S, Ascalone L, Ziegler B et al (2021) Salvage surgery in patients with local recurrence after radical prostatectomy. *Eur Urol* 79(4):537–544. <https://doi.org/10.1016/j.eururo.2020.11.012>
 23. Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 250(2):187–196. <https://doi.org/10.1097/SLA.0b013e3181b13ca2>
 24. Knipper S, Mehdi Irai M, Simon R et al (2023) Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery. *Eur Urol* 83(1):62–69. <https://doi.org/10.1016/j.eururo.2022.05.031>
 25. Van den Broeck T, van den Bergh RCN, Arfi N et al (2019) Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. *Eur Urol* 75(6):967–987. <https://doi.org/10.1016/j.eururo.2018.10.011>
 26. Ploussard G, Almeras C, Briganti A et al (2015) Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. *J Urol* 194(4):983–988. <https://doi.org/10.1016/j.juro.2015.04.103>
 27. Suardi N, Gandaglia G, Gallina A et al (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. *Eur Urol* 67(2):299–309. <https://doi.org/10.1016/j.eururo.2014.02.011>
 28. Herlemann A, Kretschmer A, Buchner A et al (2017) Salvage lymph node dissection after 68 Ga-PSMA or 18 F-FEC PET/CT for nodal recurrence in prostate cancer patients. *Oncotarget*. <https://doi.org/10.18632/oncotarget.21118>
 29. Fossati N, Suardi N, Gandaglia G et al (2019) Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis. *Eur Urol* 75(1):176–183. <https://doi.org/10.1016/j.eururo.2018.09.009>
 30. Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. *JAMA Oncol* 6(5):650–659. <https://doi.org/10.1001/jamaoncol.2020.0147>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Fabian Falkenbach¹  · **Sophie Knipper**¹ · **Daniel Koehler**² · **Francesca Ambrosini**^{1,3} · **Thomas Steuber**^{1,4} · **Markus Graefen**¹ · **Lars Budäus**¹ · **Matthias Eiber**⁵ · **Lukas Lunger**⁶ · **Flemming Lischewski**⁶ · **Matthias M. Heck**⁶ · **Tobias Maurer**^{1,4}

✉ Fabian Falkenbach
f.falkenbach@uke.de

¹ Martini-Klinik Prostate Cancer Center Hamburg-Eppendorf,
Martinistr. 52, 20246 Hamburg, Germany

² Department of Diagnostic and Interventional Radiology
and Nuclear Medicine, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany

³ Department of Urology, IRCCS Policlinico San Martino
Hospital, University of Genova, Genoa, Italy

⁴ Department of Urology, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany

⁵ Department of Nuclear Medicine, Rechts der Isar Medical
Center, Technical University of Munich, Munich, Germany

⁶ Department of Urology, Rechts der Isar Medical Center,
Technical University of Munich, Munich, Germany

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com